OverviewSuggest Edit

Immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. Natural Killer cells, or NK-cells, and T-cells belong to the most potent cells of the human defense arsenal. Affimed’s proprietary, next-generation bispecific antibodies, termed TandAbs®, are designed to bring NK-cells or T-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. Due to their novel tetravalent tandem architecture, which provides for four binding domains, the TandAbs bind to specific targets on immune and cancer cells with high affinity. In addition, TandAbs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. Affimed believes, based on preclinical and clinical data generated to date, that TandAbs have the potential to ultimately improve clinical outcomes in cancer patients and could eventually become a cornerstone of modern targeted oncology care. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights.
TypePublic
Founded2000
HQHeidelberg, DE
Websiteaffimed.com

Latest Updates

Employees (est.) (Sept 2020)137(+1270%)
Revenue (FY, 2019)$21.4 M(-9%)
Share Price (Oct 2020)$3.5 (-2%)
Cybersecurity ratingAMore

Key People/Management at Affimed N.V.

Adi Hoess

Adi Hoess

Chief Executive Officer
Thomas Hecht

Thomas Hecht

Chairman
Wolfgang Fischer

Wolfgang Fischer

Chief Operating Officer
Denise Mueller

Denise Mueller

Chief Business Officer
Andreas Harstrick

Andreas Harstrick

Chief Medical Officer (CMO)
Arndt Schottelius

Arndt Schottelius

Chief Scientific Officer (CSO)
Show more

Affimed N.V. Office Locations

Affimed N.V. has an office in Heidelberg
Heidelberg, DE (HQ)
582 Im Neuenheimer Feld
Show all (1)

Affimed N.V. Financials and Metrics

Affimed N.V. Revenue

Affimed N.V.'s revenue was reported to be $21.39 m in FY, 2019
USD

Revenue (FY, 2019)

21.4m

Net income (FY, 2019)

(32.4m)

EBIT (FY, 2019)

(32.4m)

Market capitalization (19-Oct-2020)

292.3m

Closing stock price (19-Oct-2020)

3.5

Cash (31-Dec-2019)

95.2m

EV

197.4m
Affimed N.V.'s current market capitalization is $292.3 m.
EURFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

7.6m6.3m2.0m23.7m21.4m

Revenue growth, %

(17%)(68%)

General and administrative expense

7.5m8.3m8.0m

R&D expense

22.0m30.2m21.5m
EURFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

76.7m35.4m39.8m94.8m95.2m

Accounts Receivable

915.0k2.3m1.1m

Inventories

228.0k197.0k241.0k260.0k296.0k

Current Assets

78.3m47.9m42.0m110.9m105.9m
EURFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(20.2m)(32.2m)(30.2m)(19.5m)

Depreciation and Amortization

336.0k369.0k351.0k403.0k906.0k

Inventories

(29.0k)31.0k(44.0k)

Accounts Payable

1.3m(2.2m)(1.0m)
USDFY, 2015

Revenue/Employee

130.4k

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.2 x
Show all financial metrics

Affimed N.V. Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Affimed N.V. Online and Social Media Presence

Embed Graph

Affimed N.V. Blogs

Affimed Announces Appointment of Arndt Schottelius, M.D. Ph.D. as Chief Scientific Officer

Der Beitrag Affimed Announces Appointment of Arndt Schottelius, M.D. Ph.D. as Chief Scientific Officer erschien zuerst auf Affimed.

Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters’ Option to Purchase Additional Shares

Der Beitrag Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters’ Option to Purchase Additional Shares erschien zuerst auf Affimed.

Affimed Announces Proposed Public Offering of Common Shares

Der Beitrag Affimed Announces Proposed Public Offering of Common Shares erschien zuerst auf Affimed.

Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers

Der Beitrag Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers erschien zuerst auf Affimed.

Affimed Highlights Progress on NK Cell Engager Collaboration with Genentech

Der Beitrag Affimed Highlights Progress on NK Cell Engager Collaboration with Genentech erschien zuerst auf Affimed.

Affimed Reports Second Quarter 2019 Financial and Operational Results

Der Beitrag Affimed Reports Second Quarter 2019 Financial and Operational Results erschien zuerst auf Affimed.
Show more

Affimed N.V. Frequently Asked Questions

  • When was Affimed N.V. founded?

    Affimed N.V. was founded in 2000.

  • Who are Affimed N.V. key executives?

    Affimed N.V.'s key executives are Adi Hoess, Thomas Hecht and Wolfgang Fischer.

  • How many employees does Affimed N.V. have?

    Affimed N.V. has 137 employees.

  • What is Affimed N.V. revenue?

    Latest Affimed N.V. annual revenue is $21.4 m.

  • What is Affimed N.V. revenue per employee?

    Latest Affimed N.V. revenue per employee is $156.1 k.

  • Who are Affimed N.V. competitors?

    Competitors of Affimed N.V. include Array BioPharma, Amicus Therapeutics and Zogenix.

  • Where is Affimed N.V. headquarters?

    Affimed N.V. headquarters is located at 582 Im Neuenheimer Feld, Heidelberg.

  • Where are Affimed N.V. offices?

    Affimed N.V. has an office in Heidelberg.

  • How many offices does Affimed N.V. have?

    Affimed N.V. has 1 office.